Qualcomm

$90.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.33 (-0.36%) Today
+$0.07 (+0.08%) As of 5:08 PM EST after-hours

Why Robinhood?

You can buy or sell Qualcomm and other stocks, options, ETFs, and crypto commission-free!

About QCOM

QUALCOMM, Inc. engages in the development, design, and provision of digital telecommunications products and services. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). Read More The QCT segment develops and supplies integrated circuits and system software based on technologies for the use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Employees
37,000
Headquarters
San Diego, California
Founded
1985
Market Cap
110.39B
Price-Earnings Ratio
25.31
Dividend Yield
3.24
Average Volume
13.64M
High Today
$91.98
Low Today
$89.28
Open Price
$90.77
Volume
10.28M
52 Week High
$94.11
52 Week Low
$49.10

Collections

QCOM News

BenzingaNov 11

Morgan Stanley Downgrades Qualcomm On Valuation

Morgan Stanley has stepped to the sidelines on Qualcomm, Inc. (NASDAQ: QCOM), saying there's no longer the valuation gap with the company's semiconductor peers
63
Washington PostNov 11

Tupperware, Qualcomm fall; Walgreens, SunPower rise

The drugstore operator is a potential buyout target for private equity firm KKR, according to Bloomberg. Nektar Therapeutics, up 94 cents to $20.98 The drug d
725

QCOM Earnings

$0.70
$0.87
$1.03
$1.20
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
$0.70 per share
Actual
$0.78 per share

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.